Zydelig is indicated for patients with relapsed chronic lymphocytic leukemia in combination with rituximab for whom rituximab alone would be considered appropriate therapy; as monotherapy for patients with relapsed follicular B-cell non-Hodgkin lymphoma; and for small lymphocytic lymphoma patients who have received at least two prior systemic therapies.
A curious piece of paper hangs in a frame outside the director’s office at University of Iowa Holden Comprehensive Cancer Center on the second floor of the General Hospital.
